Several prospective clinical trials have demonstrated that DNA damage-related treatment based on BRCA gene mutation may be a safe and efficient treatment for BRCA1/2-deficient pancreatic cancers (40, 41). This evidence concerns the gene BRCA1 and pancreatic neoplasm.